The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.